Form 4: TPG GP A, LLC Reports Beneficial Ownership Changes in Sionna Therapeutics Following IPO
SEC Form 4
TPG GP A, LLC, along with James G. Coulter and Jon Winkelried, reported changes in beneficial ownership of Sionna Therapeutics common stock following the company's initial public offering on February 10, 2025.
Summary
- TPG GP A, LLC, James G. Coulter, and Jon Winkelried filed a Form 4 detailing changes in their beneficial ownership of Sionna Therapeutics, Inc. (SION) common stock.
- The filing reflects transactions related to Sionna Therapeutics' initial public offering (IPO) on February 10, 2025.
- Preferred stock automatically converted into common stock upon the IPO at a rate of one common share per 1.4611 preferred share.
- The Rise Fund Sling, L.P. acquired 1,125,000 shares of common stock at $18.00 per share in connection with the IPO.
- Following the reported transactions, the Reporting Persons beneficially own 6,684,962 shares of Common Stock indirectly.
- The Reporting Persons disclaim beneficial ownership of the securities reported herein, except to the extent of such TPG Fund's or such Reporting Person's pecuniary interest therein, if any.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The filing reflects standard procedures following an IPO, with no immediately apparent negative implications. The investment by The Rise Fund Sling, L.P. is a positive sign.
Positives
- The IPO was successfully completed, resulting in the conversion of preferred stock to common stock.
- The Rise Fund Sling, L.P. made a significant investment in Sionna Therapeutics by purchasing 1,125,000 shares at $18.00 per share.
Industry Context
Form 4 filings are standard practice following significant transactions like IPOs, providing transparency into the ownership structure of publicly traded companies. This filing indicates the ownership changes resulting from Sionna Therapeutics' IPO and the investment activity of related entities.
Comparison to Industry Standards
- Form 4 filings are a standard regulatory requirement for insiders of publicly traded companies, ensuring transparency in ownership changes.
- The reported transactions are typical for venture capital firms like TPG following an IPO of a portfolio company.
- The conversion of preferred stock to common stock is a common mechanism in venture-backed companies upon reaching a liquidity event like an IPO.
Stakeholder Impact
- Shareholders: The filing provides transparency regarding ownership changes following the IPO.
- Employees: The successful IPO and subsequent investment could boost employee morale.
- Customers: No direct impact on customers is apparent from this filing.
Key Dates
| Date | Description |
|---|---|
| 2024-01-10 | Date of authorization and designation letters for Gerald Neugebauer to sign on behalf of Messrs. Coulter and Winkelried. |
| 2025-02-10 | Date of Sionna Therapeutics' initial public offering (IPO) and related transactions, including the conversion of preferred stock and the purchase of common stock by The Rise Fund Sling, L.P. |
| 2025-02-12 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.